Bicycle Therapeutics plc
NASDAQ Global SelectTotal Valuation
Bicycle Therapeutics plc carries a market capitalization of 291.46M, placing it among publicly traded companies globally. Its enterprise value stands at -222.12M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 291.46M |
| Enterprise Value | -222.12M |
Share Statistics
Bicycle Therapeutics plc currently has 69.81M shares outstanding.
| Shares Outstanding | 69.81M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 5.07, and the price-to-book ratio stands at -0.34.
| PE Ratio | N/A |
| PS Ratio | 5.07 |
| PB Ratio | -0.34 |
| P/TBV Ratio | 0.58 |
| P/FCF Ratio | -1.42 |
| P/OCF Ratio | -1.40 |
Financial Position
Bicycle Therapeutics plc maintains a current ratio of 12.66, meaning it holds 12.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.77, indicating elevated leverage, while an interest coverage ratio of -1,169.38 demonstrates limited ability to service its debt obligations.
| Current Ratio | 12.66 |
| Quick Ratio | 12.28 |
| Debt / Equity | 2.77 |
| Debt / EBITDA | -0.06 |
| Interest Coverage | -1,169.38 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -28.51 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 1.41M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Bicycle Therapeutics plc's stock has declined approximately -50.35461% over the past 52 weeks. The 50-day moving average sits at 4.76, while the 200-day moving average is 6.28.
| Beta (5Y) | N/A |
| 52-Week Price Change | -50.35461% |
| 50-Day Moving Average | 4.76 |
| 200-Day Moving Average | 6.28 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Bicycle Therapeutics plc generated 63.50M in revenue and converted that into -219.03M in net income, yielding earnings per share of -3.16. EBITDA reached -237.38M, while operating income came in at -243.30M.
| Revenue | 63.50M |
| Gross Profit | N/A |
| Operating Income | -243.30M |
| Pretax Income | -217.62M |
| Net Income | -219.03M |
| EBITDA | -237.38M |
| EBIT | -243.30M |
| Earnings Per Share (EPS) | -3.16 |
Balance Sheet
Bicycle Therapeutics plc holds 559.47M in cash and equivalents against 15.34M in total debt, resulting in a net debt position of -559.47M. Total book value stands at -959.68M, with working capital of 570.25M providing operational flexibility.
| Cash & Cash Equivalents | 559.47M |
| Total Debt | 15.34M |
| Net Debt | -559.47M |
| Equity (Book Value) | -959.68M |
| Book Value Per Share | -13.83 |
| Working Capital | 570.25M |
Cash Flow
Bicycle Therapeutics plc produced -229.23M in operating cash flow over the past twelve months. After subtracting -2.46M in capital expenditures, free cash flow totaled -231.69M - equivalent to -3.34 per share.
| Operating Cash Flow | -229.23M |
| Capital Expenditures | -2.46M |
| Free Cash Flow | -231.69M |
| FCF Per Share | -3.34 |
Margins
Bicycle Therapeutics plc operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -383.18 and net profit margin of -344.95 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -383.18 |
| Pretax Margin | -342.73 |
| Profit Margin | -344.95 |
| EBITDA Margin | -373.86 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.04 |
| FCF Yield | -70.42 |
Scores
Bicycle Therapeutics plc posts an Altman Z-Score of -0.18, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.18 |